...The potentially game-changing results offer the promise of a completely new way of treating the disease, and represent what scientists hope will be the first of many successful antivirals. *** The new treatment, molnupiravir, created by the pharmaceutical companies Merck (MSD outside of the US) and Ridgeback Biotherapeutics, targets the virus’s life cycle, interfering with its replication by introducing errors in its genome. In this way, it soon stops being able to reproduce.
The study involved almost 800 people who were given a course of treatment when they got sick. Among the half on molnupiravir, 7 per cent ended up in hospital. In the half given a placebo, 14 per cent did. ***
Adults who took Merck's molnupiravir pill within 5 days of showing COVID-19 symptoms experienced about half the rate of hospitalization and death.— Washington Examiner (@dcexaminer) October 2, 2021
If approved by the FDA , Merck will supply approximately 1.7M courses of molnupiravir to the government. https://t.co/bEp5oBnfel